Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004562 · ClinicalTrials.gov registry record · Phase 3
Occluded Artery Trial (OAT)
A Phase 3 study of Heart Failure and Cardiovascular Diseases, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,201
- Enrollment target
- 1
- Study location
NCT00004562 is a Phase 3 study of Heart Failure and Cardiovascular Diseases that has completed, run by NYU Langone Health. The registered enrollment target is 2,201 participants, roughly in line with the 2,043-participant average among 397 other Heart Failure trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00004562, a Phase 3 study of Heart Failure and Cardiovascular Diseases, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,201 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients reduces the composite endpoint of mortality, recurrent myocardial infarction, and hospitalization for class IV congestive heart failure over an average 2.9-year follow-up with extended follow up for an average of six years. Long term follow-up of patients were completed in March 2010. Final collection of all regulatory documentation was completed June 2011.
Conditions Studied
Interventions
- DRUG Beta adrenergic blockers
- DRUG Platelet inhibitors
- PROCEDURE PTCA and stents
- DRUG ACE Inhibitors
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,201 participants |
| Start Date | 1999-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004562
The ClinicalTrials.gov registry entry for NCT00004562 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,201 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 2,043-participant average among 397 other Heart Failure trials with a reported enrollment target. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Heart Failure appearing as the primary indexed condition, and to 4 interventions - of which Beta adrenergic blockers is the first listed.
NCT00004562 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00004562 about?
NCT00004562 is a clinical study titled "Occluded Artery Trial (OAT)". The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients reduces the composite endpoint of mortality, recurrent myocardial infarction, and hospitalization for class IV congestive heart fai...
What is the current status of trial NCT00004562?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,201 participants. The study started on 1999-09. Estimated completion is 2011-06.
What conditions does trial NCT00004562 study?
This clinical trial studies the following conditions: Heart Failure, Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, Congestive.
What interventions are being tested in trial NCT00004562?
The interventions under investigation include: Beta adrenergic blockers (DRUG), Platelet inhibitors (DRUG), PTCA and stents (PROCEDURE), ACE Inhibitors (DRUG).
Who is sponsoring clinical trial NCT00004562?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004562 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.